Details of the Drug

General Information of Drug (ID: DMDP6UF)

Drug Name

SCH-721015

Synonyms

RAd-IFN, Merck & Co; RAd-IFN, Schering-Plough; Ad.hIFN-alpha2b, Merck & Co; Recombinant adenovirus vector expressing hybrid-interferon (bladder neoplasm), Merck & Co

Indication

Disease Entry	ICD 11	Status	REF
Mesothelioma	2C51.2	Phase 1	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D0NI0X

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-alpha 2 (IFNA2)	TTSIUJ9	IFNA2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Mesothelioma

ICD Disease Classification

2C51.2

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interferon-alpha 2 (IFNA2)	DTT	IFNA2	9.31E-04	0.35	2.05

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01162785) Phase IB Intravesical Administration of SCH 721015. U.S. National Institutes of Health.
2	Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51.